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EDITORIAL
Secondary prevention after cerebral ischaemia of presumed
arterial origin: is aspirin still the touchstone?
Patients who have had a transient ischaemic attack or non-
disabling ischaemic stroke of presumed arterial origin have
an annual risk of death from all vascular causes, non-fatal
stroke, or non-fatal myocardial infarction that ranges
between 4% and 11% without treatment.1 2 In the second-
ary prevention of these vascular complications the use of
aspirin has been the standard treatment for the past two
decades. Discussions about the dose of aspirin have domi-
nated the issue for some time, although there is no
convincing evidence for any diVerence in eVectiveness in
the dose range of 30-1300 mg/day.2 3 A far greater problem
is the limited degree of protection oVered by aspirin: the
accumulative evidence from trials with aspirin alone and
only for cerebrovascular disease of presumed arterial origin
as qualifying event indicates that a dose of aspirin of at least
30 mg/day prevents only 13% of serious vascular
complications.1 2 In this commentary we use the AntiPlate-
let Trialists’ (APT) composite outcome event—death from
all vascular causes, non-fatal stroke, or non-fatal myocar-
dial infarction—unless otherwise stated. An outcome event
that takes the entire vascular burden into account is most
relevant from the perspective of a patient. In other words
87% of the major arterial complications are not avoided
with aspirin. The question therefore is: Do we have some-
thing “stronger”?
Until recently the only alternative drug was ticlopidine.
A direct comparison with aspirin was made in the Ticlopi-
dine Aspirin Stroke Study (TASS).4 A total of 3069
patients with transient or non-disabling cerebral ischaemia
were randomised between ticlopidine (250 mg twice daily)
or aspirin (650 mg twice daily). The occurrence of
non-fatal myocardial infarction was not reported in the
original document,4 but data on the APT composite event
were reported later.1 The relative risk reduction (RRR) was
a 6% advantage in favour of ticlopidine, but the 95% con-
fidence interval (95%CI) was compatible with no diVer-
ence at all (−7 to 17%).5 Thus ticlopidine is about as eVec-
tive as aspirin. A major disadvantage is, however, that it is
definitely more toxic. Diarrhoea and skin rashes were
reported in up to 20 and 14%, respectively, and neutrope-
nia in about 1%.4
In the past 2 years three trials in patients with cerebral
ischaemia of presumed arterial origin also tried to find a
more eYcacious treatment than aspirin, in diVerent
ways.6–9
CAPRIE
CAPRIE6 was a randomised, blinded, international trial
designed to assess the relative eYcacy of clopidogrel (75
mg daily) and aspirin (325 mg daily) in reducing the risk of
the composite outcome event vascular death, non-fatal
stroke, or non-fatal myocardial infarction.6 Clopidogrel is a
new thienopyridine derivative, chemically related to
ticlopidine. Patients from three diagnostic strata partici-
pated: ischaemic stroke (6431), myocardial infarction
(6302), and peripheral arterial disease (6452). The overall
RRR by clopidogrel versus aspirin was 8.7% (95% CI 0.3-
16.5). The trialists based the design of the trial on the
assumption that the three presentations of arterial disease
are all expressions of a single underlying disease—
atherosclerosis. Their data, however, do not necessarily
support the quantitative implications of such a view. The
RRRs diVered significantly (p=0.042) between the strata:
7.3% for ischaemic stroke,−3.7% for myocardial infarc-
tion, and 23.8% for peripheral arterial disease. The RRRs
(for the APT standard outcome) reported by the APT
Collaboration (mainly based on aspirin trials) also diVer
according to indication: unstable angina 35%, acute myo-
cardial infarction 25%, previous myocardial infarction
22%, and cerebral ischaemia 18%. Thus the magnitude of
the risk reduction conferred by drug treatment may
depend on the type of arterial disease.1 For the stroke sub-
group in CAPRIE, the point estimate of the RRR is a
modest 7.3%: the absolute risk reduction is 0.56%/year,
and the number needed to be treated with clopidogrel for
1 year instead of aspirin to avoid one vascular event is
therefore about 200. Furthermore, the 95% CI in the
stroke stratum is wider than for all patients (−5.7 to 18.7)
and includes the interpretation that clopidogrel is not bet-
ter than aspirin at all. The modest advantage of clopidog-
rel over aspirin after stroke is similar to that obtained with
ticlopidine compared with aspirin (6%). On the other
hand, clopidogrel does not have the toxic side eVects of
ticlopidine which necessitated haematological monitoring.
Because of the small advantage of clopidogrel, both in the
stroke stratum and overall, and the high cost of the drug
(wholesale price about $1000/year in the United States),
clopidogrel is not attractive as a drug of first choice in
patients after cerebral ischaemia, but may be used as a safe
second line alternative.
ESPS-2
The second European Stroke Prevention Study
(ESPS-2)7 8 was a randomised, placebo controlled, double
blind trial comparing the eVects of low dose aspirin (50 mg
daily), modified release dipyridamole (400 mg daily), and
the combination of both drugs with that of placebo in 6602
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patients with a previous ischaemic stroke or transient
ischaemic attack.7 Primary outcome events were stroke,
death, and stroke and death together. The trial showed a
benefit for the combination therapy in comparison with
aspirin alone for the occurrence of stroke (relative risk
(RR) 0.76; 95% CI 0.63 - 0.93), a marginally statistically
significant diVerence for the combination of stroke and
death (RR 0.87; 95% CI 0.75-1.00), and no diVerence for
total mortality (RR 1.02; 95% CI 0.84-1.23).
The main paper does not report on the APT standard
outcome event, but in a more recent publication these data
were given: the RR of aspirin plus dipyridamole versus
aspirin only was 0.78 (95% CI 0.67-0.91).8
The RR of aspirin versus placebo for (APT) vascular
events was 0.87 (95% CI 0.76-1.00).8 Some might
interpret the protective eVect of 13% with 50 mg of aspirin
as evidence that this is too low a dose, given that this effect
is less than the 24% risk reduction generally attributed to
aspirin, in any dose and for any indication.1 However, we
pointed out above that for the prevention of stroke alone
risk reductions with aspirin have always been in this order
of magnitude and were already known at the start of
ESPS-2.2 Therefore, the relevant question considered by
ESPS-2 was whether aspirin plus dipyridamole was more
eYcacious than aspirin alone.
Four earlier studies compared the eYcacy of combina-
tion therapy and aspirin alone10–13; data on these studies
have been listed in an appendix of the report on the second
cycle of the APT Collaboration.1 The unpublished and
therefore often forgotten study by Kaye enrolled stroke
patients and studied deep venous thrombosis as primary
outcome and vascular events as secondary outcomes.13 A
systematic review of these four studies for the composite
outcome event vascular death, stroke, or myocardial
infarction yields a Mantel-Haenszel RR of 0.97 (95% CI
0.78-1.22; figure). This is strikingly—although not
significantly—diVerent from the result obtained in
ESPS-2, also if Kaye’s small study is omitted (cumulative
RR 0.95; 95% CI 0.75-1.19). A similar discrepancy exists
between the ESPS-2 primary outcome measure“‘stroke or
death” RR of 0.87 (95% CI 0.75-1.00) for ESPS-2 and
1.01 (95% CI 0.82-1.25) for the four earlier studies taken
together. If the results of all five trials are combined, despite
the discrepancy described above, the overall RRR is 16%
(95% CI 5-26%) (figure). For total deaths, the comparison
of the combination of aspirin and dipyridamole versus
aspirin alone showed no benefit (RR=1.02) nor for vascu-
lar death (RR=0.99; 95% CI 0.77-1.27).8 This suggests
that any beneficial eVect of the combination may apply,
especially to non-fatal events.
A Bayesian approach to the interpretation of ESPS-2
may be as follows.14 15 Firstly, assume one was (as we were)
sceptical about the possible eYcacy of the combination of
aspirin and dipyridamole (a priori opinion).10–13 16 Then the
ESPS-2 results show a statistically significant reduction in
RR of 22% for major vascular events in favour of the com-
bination of aspirin and dipyridamole versus aspirin alone.
Finally, the a posteriori opinion is to be less sceptical and
wonder whether there might after all be a true benefit of the
combination therapy above aspirin alone. To be convinced
one will seek confirmation by another Bayesian update of
opinion—that is, by the results of a new clinical trial.
Clearly, for those clinicians who were less sceptical from
the outset the ESPS-2 data will be convincing in their own
right. However, even in that situation the costs of addition
of dipyridamole to aspirin should be weighed against the
perceived clinical benefits.
SPIRIT
The aim of SPIRIT (Stroke Prevention In Reversible
Ischemia Trial)9 was to compare the eYcacy and safety of
oral anticoagulants (INR 3.0-4.5) and 30 mg aspirin daily.
Patients referred to a neurologist because of a transient
ischaemic attack or minor ischaemic stroke (Rankin
grade<3) were eligible. The primary measure of outcome
was the composite event “death from all vascular causes,
stroke, myocardial infarction, or major bleeding complica-
tion”. The trial was stopped at the first interim analysis,
when a total of 1316 patients were enrolled; their mean
follow up was 14 months. There was an excess of the pri-
mary outcome event in the anticoagulant group (81/651)
versus 36/665 in the aspirin group (hazard ratio 2.3, 95%
CI 1.6-3.5).9 This excess could be attributed to 53 major
bleeding complications (27 intracranial; 17 fatal) during
anticoagulant therapy versus six on aspirin (three intracra-
nial; one fatal). The annual bleeding incidence was 7%
overall, but it increased sharply with the achieved
INR-value. The eYcacy of a lower intensity of anticoagu-
lation is currently assessed in two trials: WARSS and
ESPRIT.17 18
The striking diVerence in incidence of intracerebral
bleeding complications between SPIRIT (3.7%/year in
patients with cerebral ischaemia of presumed arterial
origin, mean achieved INR 3.3, mean age 63 years) and the
EAFT (0.4%/year in patients with cerebral ischaemia and
atrial fibrillation, mean achieved INR 2.9, mean age 71
years)19 20 confirms the notion that not all vascular disease
is the same in its response to treatment. Therefore specific
therapy should be given for specific vascular indications.
New drugs or combinations of drugs
Glycoprotein IIb/IIIa (GP-IIb/IIIa) receptor blockers, or
GP-IIb/IIIa antagonists, block the final common pathway
of platelet aggregation by binding of fibrinogen to the
GP-IIb/IIIa receptor. Hence these drugs inhibit platelet
Relative risks with 95% CIs for all trials on the comparison of aspirin plus
dipyridamole versus aspirin alone, before 1996, in 1996, and their
combined results for the outcome event “vascular event”.
Before 1996
Guiraud-Chaumeil et al 10
AICLA11
ACCSG12
Kaye13
All
1996
ESPS-28
All
2.50.5 2.01.5
Relative risk (95% CI)
1.0
558 Algra, Koudstaal, van Gijn
 group.bmj.com on February 16, 2011 - Published by jnnp.bmj.comDownloaded from 
activation irrespective of the metabolic pathway that leads
to platelet aggregation. In patients after PTCA the mono-
clonal antibody to the GP-IIb/IIIa receptor c7E3 was
found to be promising.21 The most important side eVect
was gingival bleeding. After the placement of coronary
artery stents the combination of ticlopidine and aspirin was
more eVective than conventional anticoagulant therapy
with regard to the occurrence of both cardiac events and
haemorrhagic and vascular complications.22 The safety and
eYcacy of these new drugs or combinations have still to be
established in patients with cerebrovascular disease and
indeed several such studies are being planned.
Conclusions
x Aspirin alone (in any dose of at least 30 mg daily) con-
fers a relative risk reduction of death from all vascular
causes, non-fatal stroke, or non-fatal myocardial infarc-
tion of 13% relative to placebo treatment.
x The combination of aspirin and dipyridamole may give
an RRR of 16% (95% CI 5-26%) compared with aspirin
alone if one is prepared to overlook the striking
(although not statistically significant) disparity of
ESPS-2 with four previous studies. Another large trial
comparing the combination of aspirin plus dipyridamole
and aspirin alone seems called for.
x Clopidogrel may give a reduction in RR of 7-9%
compared with aspirin treatment, but is not an attractive
drug because the costs are considerably higher than
those of aspirin. The drug, however, has a more favour-
able safety profile than ticlopidine.
x Anticoagulation with INR 2.0-4.0 is highly eVective for
secondary prevention in atrial fibrillation, but anticoagu-
lation with INR 3.0-4.5 is not safe in the secondary pre-
vention after cerebral ischaemia of presumed arterial
origin. The eYcacy and safety of mild anticoagulation
(INR 2-3) needs further study.
x The eYcacy of new antiplatelet drugs such as GP-IIb/
IIIa receptor blockers will be studied in the years to
come.
x Combinations other than aspirin and dipyridamole
deserve to be investigated— for example, the combina-
tion of a low dose of aspirin and clopidogrel.
x Not all atherosclerotic vascular disease is necessarily the
same: the therapeutic eVect may be modified by the pre-
senting disease.
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